Preliminary findings suggest that adding bempegaldesleukin to nivolumab may improve responses in patients with metastatic melanoma. In a phase I/II trial, the combination elicited responses in 20 out of 38 patients with newly diagnosed disease and was associated with relatively few side effects.

中文翻译：

---

Bempegaldesleukin增加黑色素瘤反应。

初步研究结果表明，将尼培​​单抗加入贝培高地白蛋白可以改善转移性黑色素瘤患者的反应。在I / II期试验中，该组合在38位新诊断疾病的患者中引起了20位的反应，并且副作用相对较少。